


AZ-Dyrk1B-33

| | | | |
|---------------------------|--|-------|----------|
| Cat. No.: | HY-117391 | | |
| CAS No.: | 1679330-37-0 | | |
| Molecular Formula: | C ₁₉ H ₁₆ N ₄ | | |
| Molecular Weight: | 300.36 | | |
| Target: | DYRK | | |
| Pathway: | Protein Tyrosine Kinase/RTK | | |
| Storage: | Powder | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 6 months |
| | | -20°C | 1 month |



SOLVENT & SOLUBILITY

| | | | | | |
|---|---|--------------------------|--------------|------------|------------|
| In Vitro | DMSO : 125 mg/mL (416.17 mM; Need ultrasonic) | | | | |
| | | Solvent Concentration | Mass 1 mg | 5 mg | 10 mg |
| | Preparing Stock Solutions | 1 mM | 3.3293 mL | 16.6467 mL | 33.2934 mL |
| | | 5 mM | 0.6659 mL | 3.3293 mL | 6.6587 mL |
| 10 mM | | 0.3329 mL | 1.6647 mL | 3.3293 mL | |
| Please refer to the solubility information to select the appropriate solvent. | | | | | |
| In Vivo | <ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (6.93 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (6.93 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (6.93 mM); Clear solution | | | | |

BIOLOGICAL ACTIVITY

| | |
|-------------------------------------|--|
| Description | AZ-Dyrk1B-33 is a potent and selective Dyrk1B kinase inhibitor, with an IC ₅₀ of 7 nM ^[1] . |
| IC₅₀ & Target | DYRK1B |
| In Vitro | <p>AZ-Dyrk1B-33 shows inhibition of phosphorylation of Dyrk pS421 in cells with an IC₅₀ of 0.192 μM^[1].</p> <p>AZ-Dyrk1B-33 shows no effect in sensitization^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> |

CUSTOMER VALIDATION

- Research Square Print. October 19th, 2022.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Kettle JG, et al. Discovery and optimization of a novel series of Dyrk1B kinase inhibitors to explore a MEK resistance hypothesis. J Med Chem. 2015 Mar 26;58(6):2834-44.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA